OTCMKTS:PHGUF

Pharming Group Q1 2026 Earnings Results & Report

Pharming Group logo
$1.26 0.00 (0.00%)
As of 11/13/2026

Pharming Group missed analyst expectations on both earnings and revenue in its Q1 2026 results, released May 7, 2026. The company reported EPS of -$0.01 versus the $0.0001 consensus estimate, while revenue of $72.45 million fell short of the $92.06 million estimate by $19.61 million.

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
Before Market Opens

Pharming Group EPS Results

Actual EPS
-$0.01
Consensus EPS
$0.0001
Beat/Miss
Missed by -$0.0101
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 5 quarters

Pharming Group Revenue Results

Actual Revenue
$72.45 million
Expected Revenue
$92.06 million
Beat/Miss
Missed by -$19.61 million
YoY Revenue Growth
N/A

Conference Call Resources

Pharming Group Q1 2026 Earnings FAQ

Pharming Group (OTCMKTS:PHGUF) reported earnings of -$0.01 per share for Q1 2026, missing the consensus estimate of $0.0001. The report was announced on Thursday, May 7, 2026.

Pharming Group reported revenue of $72.45 million for Q1 2026, against a consensus estimate of $92.06 million.

Pharming Group Earnings Headlines

I'm handing you this one free
Elon Musk doesn't own the chip powering every Tesla, every Starlink dish, and every AI satellite he builds. He licenses it from one overlooked company. That supplier just got a major catalyst. Musk filed to launch 1,000,000 satellites, a move analyst Dylan believes could drive a 100X bigger bill for this chipmaker starting December 8th.tc pixel
See More Pharming Group Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pharming Group? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pharming Group and other key companies, straight to your email.

About Pharming Group

Pharming Group (OTCMKTS:PHGUF) is a biotechnology company based in Leiden, the Netherlands, focused on developing and commercializing medicines for rare diseases. Its portfolio includes treatments for hereditary angioedema and activated phosphoinositide 3-kinase delta syndrome (APDS).

The company’s products include Ruconest (conestat alfa), a recombinant human C1 esterase inhibitor used to treat acute hereditary angioedema attacks, and Joenja (leniolisib), an oral treatment for APDS. Pharming developed Ruconest using a production process involving genetically modified rabbits.

Founded in 1988, Pharming serves patients in markets including the United States and Europe, with additional access supported through commercial partners. Its work also includes research and development of medicines for other rare diseases.

View Pharming Group Profile